Kaitlyn D’Onofrio

DocwireNews

The Food and Drug Administration (FDA) has approved another&nbsp;biosimilar adalimumab,&nbsp;marketed as&nbsp;Hyrimoz&nbsp;(adalimumab-adaz), in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn&rsquo;s disease, ulcerative colitis, and plaque psoriasis.&nbsp;The latest treatment is the U.S.&rsquo;s third biosimilar to Humira (adalimumab), following&nbsp;Amjevita&nbsp;(adalimumab-atto) and&nbsp;Cyltezo&nbsp;(adalimumab-adbm).&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/FDAapproves?src=hash&amp;ref_src=twsrc%5Etfw">#FDAapproves</a> Hyrimoz (adalimumab-adaz), biosimilar to Humira (adalimumab): <a href="https://t.co/7nCByZVsbE">https://t.co/7nCByZVsbE</a>. Learn more about <a href="https://twitter.com/hashtag/biosimilars?src=hash&amp;ref_src=twsrc%5Etfw">#biosimilars</a> here: <a href="https://t.co/NDseaneArN">https://t.co/NDseaneArN</a>. <a href="https://t.co/mrr3VsEAHi">pic.twitter.com/mrr3VsEAHi</a>
&mdash; FDA Drug Information (@FDA_Drug_Info) <a href="https://twitter.com/FDA_Drug_Info/status/1057651850470678529?ref_src=twsrc%5Etfw">October 31, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Hyrimoz&nbsp;is manufactured by Sandoz, a division of Novartis.&nbsp;The FDA&rsquo;s approval comes after a&nbsp;phase 3 randomized, double-blind, controlled, 51-week study&nbsp;that compared the efficacy of&nbsp;Hyrimoz&nbsp;against Humira&nbsp;in adult patients with active, clinically stable, moderate-to-severe plaque psoriasis.&nbsp;Patients were randomly assigned to receive 80 mg of&nbsp;Hyrimoz&nbsp;(n = 231) or Humira (n = 234) at baseline, then 40 mg biweekly from week one. After 17 weeks, patients either switched (n = 126) or continued treatment (n = 253).&nbsp;At week 16, 66.8% of&nbsp;Hyrimoz&nbsp;patients and 65% of Humira patients achieved&nbsp;&ge; 75% improvement in Psoriasis Area and Severity Index (PASI 75)&nbsp;(95% CI -7.46 to 11.15). From weeks 17 to 51, PASI improved overtime and was similar between the switched and continued treatment groups. Researchers observed no safety or immunogenicity differences between the two groups after 16 weeks or from weeks 17 to 51, and no patients experienced hypersensitivity to adalimumab upon switching.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
FDA Approves <a href="https://twitter.com/hashtag/Hyrimoz?src=hash&amp;ref_src=twsrc%5Etfw">#Hyrimoz</a> (adalimumab-adaz), a Biosimilar to <a href="https://twitter.com/hashtag/Humira?src=hash&amp;ref_src=twsrc%5Etfw">#Humira</a> &ndash; <a href="https://t.co/RKgRqR0vak">https://t.co/RKgRqR0vak</a>
&mdash; Drugs.com (@Drugscom) <a href="https://twitter.com/Drugscom/status/1057778056721510405?ref_src=twsrc%5Etfw">October 31, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>According to the FDA, the most common adverse reactions (incidence &gt; 10%) were infections, injection site reactions, headache, and rash.&nbsp;&ldquo;Biosimilars can help people suffering from chronic, debilitating conditions gain expanded access to important medicines that may change the outcome of their disease,&rdquo; said Stefan Hendriks,&nbsp;global head of biopharmaceuticals&nbsp;for&nbsp;Sandoz, in a statement. &ldquo;With the FDA approval of&nbsp;Hyrimoz, Sandoz is one step closer to offering US patients with autoimmune diseases the same critical access already available in Europe.&rdquo;&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/risankizumab-moderate-plaque-psoriasis/">Risankizumab&nbsp;for Moderate-to-severe Plaque Psoriasis</a>&nbsp;<a href="https://proddocwire.wpengine.com/gastroenterology/a-real-life-comparison-of-the-effectiveness-of-adalimumab-and-golimumab-in-moderate-to-severe-ulcerative-colitis-supported-by-propensity-score-analysis/">A&nbsp;real life&nbsp;comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by Propensity Score analysis.</a>&nbsp;<a href="https://proddocwire.wpengine.com/rheumatology/the-biosimilar-roundup/">The Biosimilar Roundup</a>&nbsp;<a href="https://proddocwire.wpengine.com/gastroenterology/effectiveness-and-safety-of-anti-tnf-therapy-for-inflammatory-bowel-disease-in-liver-transplant-recipients-for-primary-sclerosing-cholangitis-a-nationwide-case-series/">Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series</a>&nbsp;Source:&nbsp;<a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761071lbl.pdf">FDA</a>, <a href="https://www.healio.com/rheumatology/rheumatoid-arthritis/news/online/%7Bebc9eef8-4f04-43fe-b875-7510cfaeb82e%7D/fda-approves-hyrimoz-third-humira-biosimilar">Healio</a>, <a href="https://www.sandoz.com/news/media-releases/sandoz-receives-us-fda-approval-biosimilar-hyrimoz-adalimumab-adaz">Sandoz</a>,&nbsp;<a href="https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.16890">British Journal of Dermatology</a>

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

FDA Approves Biosimilar Adalimumab

Rheumatology

The Food and Drug Administration (FDA) has approved another biosimilar adalimumab, marketed as Hyrimoz (adalimumab-adaz), in the treatment of rheumatoid arthritis, ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe